Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- Citation:
- J Clin Oncol vol 29 (25) 3366-3373
- Year:
- 2011
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Long-Term-Followup
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 1
- Parents:
- 549
- Children:
- None
- Pharmas:
- Grants:
- U10 CA012027, R01-CA129949, U10 CA069651, U10-CA69651, R01 CA129949, U10 CA069974, U10-CA25224, U10-CA37377, U10 CA025224, U10-CA12027, U10 CA037377
- Corr. Author:
- Authors:
- Edith A. Perez Edward H. Romond Vera J. Suman Jong-Hyeon Jeong Nancy E. Davidson Charles E. Geyer Silvana Martino Eleftherios P. Mamounas Peter A. Kaufman Norman Wolmark
- Networks:
- Study
- NCCTG-N9831
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords:
- Bc5, Bc6, Original Reports, Breast Cancer